Full Press Release Details
Rhythm Pharmaceuticals Announces IMCIVREE setmelanotide Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet Biedl Syndrome.
RYTM
Rhythm Pharmaceuticals Announces IMCIVREE setmelanotide Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet Biedl Syndrome
Key Takeaway: Rhythm Pharmaceuticals Announces IMCIVREE setmelanotide Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet Biedl Syndrome